Randomized Trialhigh evidence
Intensive LDL Cholesterol Targeting in Atherosclerotic Cardiovascular Disease.
The New England journal of medicine·April 9, 2026·PMID 41910315
Why it mattersThis trial provides direct randomized evidence supporting the more aggressive LDL-C goal of <55 mg/dL over the traditional <70 mg/dL in secondary prevention, addressing a key evidence gap in lipid management guidelines.
The papers that matter, first.
MedLit ranks the medical literature into a specialty feed with concise summaries, evidence-aware triage, and visual takeaways.
§
MedLit · Evidence, Distilled